ACE and diabetic kidney disease: In current clinics of DKD, despite improvements in glycemic control and advances in reno-protective therapies, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB), there is a large residual risk of ESKD onset and progression [8,9].